Cosyntropin is an adrenocorticotropic hormone indicated , in combination with other diagnostic tests, for use as a diagnostic agent in the screening of adrenocortical insufficiency in adults and pediatric patients. MedsAcross supplies Cosyntropin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
CORTROSYN is indicated, in combination with other diagnostic tests, for use as a diagnostic agent in the screening of adrenocortical insufficiency in adults and pediatric patients. CORTROSYN is an adrenocorticotropin hormone indicated, in combination with other diagnostic tests, for use as a diagnostic agent in the screening of adrenocortical insufficiency in adults and pediatric patients.
Source: US FDA prescribing information
Cosyntropin exhibits the full corticosteroidogenic activity of natural ACTH. Various studies have shown that the biologic activity of ACTH resides in the N-terminal portion of the molecule and that the 1-20 amino acid residue is the minimal sequence retaining full activity. Partial or complete loss of activity is noted with progressive shortening of the chain beyond 20 amino acid residues. For example, the decrement from 20 to 19 results in a 70% loss of potency. The pharmacologic profile of CORTROSYN is similar to that of purified natural ACTH. It has been established that 0.25 mg of CORTROSYN will stimulate the adrenal cortex maximally and to the same extent as 25 units of natural ACTH. This dose of CORTROSYN will produce maximal secretion of 17-OH corticosteroids, 17-ketosteroids and/or 17-ketogenic steroids.
Source: US FDA prescribing information
In general, stop glucocorticoids and spironolactone on the day of CORTROSYN testing. For long-acting glucocorticoids, stop for a longer period before CORTROSYN testing. For adults, the recommended dose is 0.25 mg to be administered by intravenous or intramuscular injection. For pediatric patients, the recommended dose to be administered by intravenous or intramuscular injection is: • 0.125 mg for patients birth to less than 2 years of age • 0.25 mg for patients 2 to 17 years of age Obtain blood samples for serum cortisol level at baseline and exactly 30 and 60 minutes after CORTROSYN administration. See Full Prescribing Information for reconstitution and interpretation of cortisol levels information.
Source: US FDA prescribing information
CORTROSYN is contraindicated in patients with a history of hypersensitivity to cosyntropin or to any excipients of CORTROSYN. Reactions have included anaphylaxis.
Source: US FDA prescribing information
Hypersensitivity: reactions including anaphylaxis have been reported. Monitor patients for hypersensitivity reactions and treat as needed. Diagnostic Inaccuracies: Cortisol levels and subsequent diagnosis of adrenocortical insufficiency following CORTROSYN administration may be inaccurate if patients are on certain medications because of their effect on cortisol or cortisol binding globulin levels. Any condition that elevates or lowers cortisol binding globulin levels may increase or decrease plasma total cortisol levels, respectively.
Source: US FDA prescribing information
Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been identified during post approval use of CORTROSYN: anaphylactic reaction bradycardia tachycardia hypertension peripheral edema rash Most common adverse reactions are: anaphylactic reaction, bradycardia, tachycardia, hypertension, peripheral edema, and rash
Source: US FDA prescribing information
Drug effects on plasma cortisol levels: • Accuracy of the test results can be affected by concomitant medications. • Glucocorticoids and spironolactone: May falsely elevate plasma cortisol levels. Stop these drugs on day of CORTROSYN testing. Long-acting glucocorticoids may need to be stopped for a longer period before CORTROSYN testing. • Estrogen: May elevate plasma total cortisol levels. Stop estrogen containing drugs 4 to 6 weeks before CORTROSYN testing.
Source: US FDA prescribing information
Store at 20º to 25ºC (68º to 77ºF), excursions permitted between 15° to 30°C (59° to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Cosyntropin, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Cosyntropin 0.25 mg/mL powder for injectionIntravenousGeneric name | — | US FDA | Available on request |
| Cortrosyn 0.25 mg/mL powder for injectionIntramuscular, intravenous | Amphastar Pharmaceuticals | US FDA | Available on request |
| Cosyntropin 0.25 mg/mL powder for injectionIntramuscular, intravenous, parenteralGeneric name | — | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 22 April 1970 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 3 presentations of Cosyntropin and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Cosyntropin, including Cortrosyn.
Yes. The US FDA first approved Cosyntropin on 22 April 1970, according to Drugs@FDA.
No listed presentation of Cosyntropin is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Cosyntropin is classified under ATC code H01AA02 (Cosyntropin).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.